EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Phase III randomized controlled trial of gefitinib versus chemotherapy in EGFR-positive treatment-naïve metastatic lung cancer: Long-term outcome after eight years

Ajaykumar Singh, Vijay Patil, Nandini Menon, Sucheta More, Srushti Jain, Supriya Goud, Darshit Shah, Minit Shah, Kunal Jobanputra, Ahmad Ubharay

Cancer Research, Statistics, and Treatment · 2024-01 · 7 (1) · 19-26

DOI: 10.4103/crst.crst_307_23 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cancer Research, Statistics, and Treatment, online erschienen am 25.03.2024. Verfasst von Ajaykumar Singh und 9 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This was the first Phase III randomized study comparing an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), gefitinib, to standard-of-care chemotherapy (pemetrexed + carboplatin followed by pemetrexed maintenance) in advanced EGFR- mutated lung cancer. The initial interim analysis showed the superiority of gefitinib over chemotherapy in terms of progression-free survival (PFS), objective response rate (ORR), and safety.

Objectives

We aimed to evaluate the long-term outcomes. Our primary endpoint was to evaluate the overall survival (OS) and the secondary endpoints were progression-free survival 2 (PFS2) and duration of response (DOR). Materials and Methods: This was a Phase III open-label, randomized, parallel-group study conducted in the Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India, in patients with EGFR mutation-positive treatment-naïve Stage IIIB or IV lung adenocarcinoma. Patients were randomized to gefitinib (250 mg orally daily) or carboplatin (area under the curve 5) and pemetrexed (500 mg/m 2 ) chemotherapy, followed by maintenance pemetrexed (500 mg/m 2 ).

Results

Between February 2012 and April 2016, 290 patients were randomized:145 to each arm. At a median follow-up of 104 months, all 290 (100%) patients had progressed, and 287 (99%) deaths had occurred. The median OS in the gefitinib arm was 19.5 months (95% confidence interval [CI], 16.7-24.8) compared to 22.6 months (95% CI, 19.2-25.2) in the chemotherapy arm; hazard ratio [HR], 1.11; 95% CI, 0.87-1.39; P, 0.423. The median PFS2 in the gefitinib arm was 15.5 months (95% CI, 13.5-18.1) compared to 12.5 months (95% CI, 11.1-14.5) in the chemotherapy arm; HR, 0.86 (95% CI, 0.66-1.13); P, 0.270. The median DOR was improved in the gefitinib arm (7.6 months; 95% CI, 5.45-9.88) compared to 3.9 months (95% CI, 3.49-6.35) in the chemotherapy arm; HR, 0.59; 95% CI, 0.42-0.82; P, 0.002. The 5-year survival was 4.1% in the gefitinib arm versus 6.8% in the chemotherapy arm.

Conclusions

This study establishes the advantages of first-line EGFR TKI therapy over chemotherapy in terms of a durable response and numerically superior PFS2. Due to crossover post-progression, there was is no significant difference in OS (Clinical Trials Registry of India number: CTRI/2015/08/006113).

Zitieren

APA

Singh, A., Patil, V., Menon, N., More, S., Jain, S., Goud, S., Shah, D., Shah, M., Jobanputra, K., & Ubharay, A. (2024). Phase III randomized controlled trial of gefitinib versus chemotherapy in EGFR-positive treatment-naïve metastatic lung cancer: Long-term outcome after eight years. Cancer Research, Statistics, and Treatment, 7(1), 19-26. https://doi.org/10.4103/crst.crst_307_23

Vancouver

Singh A, Patil V, Menon N, More S, Jain S, Goud S, et al. Phase III randomized controlled trial of gefitinib versus chemotherapy in EGFR-positive treatment-naïve metastatic lung cancer: Long-term outcome after eight years. Cancer Research, Statistics, and Treatment. 2024;7(1):19-26. doi:10.4103/crst.crst_307_23

BibTeX
@article{Singh2024,
  author = {Singh, Ajaykumar and Patil, Vijay and Menon, Nandini and More, Sucheta and Jain, Srushti and Goud, Supriya and Shah, Darshit and Shah, Minit and Jobanputra, Kunal and Ubharay, Ahmad},
  title = {Phase III randomized controlled trial of gefitinib versus chemotherapy in EGFR-positive treatment-naïve metastatic lung cancer: Long-term outcome after eight years},
  journal = {Cancer Research, Statistics, and Treatment},
  year = {2024},
  volume = {7},
  number = {1},
  pages = {19--26},
  doi = {10.4103/crst.crst_307_23}
}
Kostenlos starten →